Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Novo, Pfizer bidding war for Metsera heats up with larger offers
In total, Pfizer is now willing to part with around $8.1 billion for Metsera. But Novo is offering even more.
James Waldron
Nov 4, 2025 10:18am
Sponsored
Protocol-Ready Doesn’t Mean Trial-Ready in Ovarian Cancer Clinical Trials
Nov 3, 2025 8:00am
The 2025 Biotech Graveyard
Oct 31, 2025 5:00am
Sponsored
How to get pharmaceutical treatments where they’re needed most.
Oct 6, 2025 8:00am
Pfizer pulls the plug on 11 programs
Nov 4, 2025 2:40pm
Harmony halts genetic disease program after ph. 3 failure
Nov 4, 2025 12:45pm
More News
Publisher’s note: Questex acquires The Conference Forum, Versalinx
Nov 4, 2025 12:00pm
Fierce Healthcare
Government shutdown updates: Plan to extend, reform tax credits
Nov 4, 2025 11:30am
Prelude loses CMO, pauses SMARCA2 degraders, scores Incyte cash
Nov 4, 2025 9:40am
Merck bags $700M from Blackstone, spends $150M to regain asset
Nov 4, 2025 9:15am
See more stories